Revium Rx FY26 Q2 net loss narrows 28% to USD 748,000
RVRC•Cash position and accumulated deficit
Cash and cash equivalents and short-term bank deposits totaled about USD 1.5 million at June 30, 2026; accumulated deficit was USD 26.4 million.
Quarterly loss narrows as expenses shift
Revium Rx posted a net loss of USD 748,000 for the quarter ended June 30, 2026, narrowing 28% year over year.
Operating loss improved 22% to USD 732,000, as general and administrative expense fell 47.2% to USD 289,000.
Research and development expense rose 13.3% to USD 443,000, reflecting continued work to advance its lead programs.
Nano-Mupirocin advances toward the clinic
Nano-Mupirocin advanced toward the clinic, with Israeli Ministry of Health approval on Feb. 18, 2026 to start Phase 1 trials in healthy volunteers.
Related News
Forbright Q2 FY26 net income drops 64.6% to $4.12 million; revenue rises 13.1% to $84.99 million
FRBT•
Bogota Financial Q2 net income rises 233.48% to $748,000; net interest margin widens 20 percentage points to 1.94%
BSBK•
